Aim: Familial hypercholesterolemia (FH) patients are at particular risk for premature coronary artery disease (CAD) caused by high levels of low density lipoprotein (LDL). Administration of statins enabled us to reduce LDL-C levels in heterozygous FH patients. To evaluate the impact of statins on the clinical fate of heterozygous FH, a retrospective study was performed. Methods: We analyzed the clinical influence of statins on age at the first clinical onset of CAD in 329 consecutive FH patients referred to the lipid clinic of the National Cardiovascular Center. Among 329 heterozygous FH patients, the onset of CAD was identified in 101. Results: The age at onset of CAD was 58.8 12.5 years in the 25 patients on statins at onset, significantly higher than that in the 76 patients not on statins (47.6 10.5 years) ( p 0.001). The average age at CAD onset was significantly higher after widespread use of statins (54.2 13.2 years in 48 patients; Group 1) compared to before October 1989 when statins were approved in Japan (46.9 9.6 years in 53 patients; Group 2, p 0.002). A significant difference was seen between Groups 1 and 2 in the variables, including sex, prevalence of smoking habit, LDL-C, and the use of statins, aspirin and probucol. After adjusting for these variables, only statin use was independently associated with the difference in age at CAD onset by multivariable analysis.
Introduction
Familial hypercholesterolemia (FH) is a heritable disease of high prevalence with an autosomal-dominant mode of transmission and is linked to mutations in the low-density lipoprotein (LDL) receptor or its related gene. It is characterized by phenotypes of the elevation of plasma LDL, cutaneous and tendenous xanthomas, arcus corneae, and coronary artery disease (CAD) due to premature atherosclerosis 1) . The earliest clinical sign of heterozygous FH is an elevation of plasma LDL cholesterol (LDL-C), noted as early as at birth 2) . All other clinical manifestations seem due to an increase of LDL-C in plasma. CAD is the most serious clinical manifestation and determines the prognosis of FH. According to a previous report, Japanese FH heterozygotes generally develop the first CAD event in their 40s or later for men and 50s or later for women 3) .
To reduce plasma LDL-C in FH heterozygotes, bile acid-sequestering resins have been used since the 1970s to upregulate the LDL receptor, but their effect is limited to a 10 to 20% decline because of the concomitant induction of hepatic cholesterol synthesis 4) . Statins, competitive inhibitors of a rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl (HMG) CoA reductase, were introduced onto the market in the late 1980s. Pravastatin, the first approved statin in Japan, became commercially available at the beginning of October 1989 and simvastatin one year later 5) . Synthetic analogues became available in the late 1990s, including several "strong" statins, which lower the level of LDL-C by more than 40% 6) . Many large-scale clinical trials of statins worldwide, including Japan, showed that they reduced the risk of cardiac events or stroke in hypercholesterolemic populations [7] [8] [9] [10] . Effective reduction of LDL-C by statins was also shown in FH heterozygotes 11, 12) ; however, their clinical benefits in FH patients have not been clearly demonstrated with fixed clinical endpoints. This is partly because of the extremely high risk for CAD in FH patients, thus making controlled clinical trials of sufficient size to yield significant outcomes unethical.
Aim
Substantial numbers of FH patients have been referred to and regularly treated at the lipid clinic of the National Cardiovascular Center (NCVC) since it was founded in 1977. We therefore retrospectively analyzed the clinical records of these patients to assess the impact of the introduction of statins on the clinical prognosis of FH heterozygous patients, using patient age at the development of CAD. This parameter is specific and solid for each patient and the analysis is less influenced or biased by other factors. In addition, Mabuchi and colleagues used the same parameter in their study of Japanese FH reported before statin availability 13) .
Methods

Subjects
Of the patients referred to the lipid clinic at NCVC from 1977 to 2007, 329 consecutive patients (139 men, 190 women) were diagnosed as FH heterozygotes using the criteria previously described 14) . Most of the FH patients analyzed in the present paper were referred to our lipid clinic by their general practitioner because of hypercholesterolemia. The medical records of patients were examined according to the analysis protocol approved by our institutional ethics committee (ID#M20-25-2). Of the 329 FH patients, 101 were identified as having CAD, specifically, coronary artery stenosis (more than 75%) on angiography, including 53 patients who had CAD at the first clinic visit. The other 228 patients did not have clinical or angiographic evidence of CAD. For each patient, the age at onset of CAD was determined by the first sign, ascertained by a standardized questionnaire, which included fixed clinical endpoints of CAD, administered by attending physicians at the clinic. The compliance with statins was evaluated from the medical records.
Clinical Risk Factors
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared (kg/m 2 ). Hypertension was defined as the use of antihypertensive drugs or a blood pressure level higher than 140 mmHg systolic or 90 mmHg diastolic or both at the first clinic visit (the criteria for hypertension of the Japanese Society of Hypertension Guidelines) 15) . Diabetes mellitus was defined according to the 2002 Guideline for the Treatment of Diabetes Mellitus of the Japan Diabetes Society 16) . A family history of CAD was identified by the standardized questionnaire. Smoking was identified from patients' self-reporting. Achilles tendon thickness was measured as previously described 17) .
Analysis of Serum Lipids
Fasting plasma lipid concentration was measured before any lipid-lowering treatment. Total cholesterol (TC), triglycerides (TG), and HDL cholesterol (HDL-C) levels were measured enzymatically using an automated system in the clinical laboratory of the NCVC. LDL-C level was calculated by the Friedewald formula when the TG level was less than 400 mg/dL; three patients with TG level more than 400 mg/dL were omitted from this particular analysis. TG values were expressed as the median, (range), and logarithmically transformed before analysis.
Statistical Analysis
Statistical analysis was performed using the SPSS 15.0 (SPSS Inc., Chicago, IL) program. Parametric values are expressed as the mean standard deviation (SD). The statistical significance of differences in continuous variables was evaluated by Student's t test for unpaired data or ANOVA. The Pearson's 2 test was used to assess differences in the distribution of categorical traits.
Results
Patient Background
The baseline clinical characteristics of the 329 heterozygous FH patients analyzed in this study are shown in Table 1 . Their plasma lipid and lipoprotein profiles are similar to patients in previous reports of Japanese FH 3, 18) . Patients with CAD were older, had higher levels of BMI, TC, and LDL-C, lower HDL-C, and a higher incidence of diabetes mellitus, hypertension, a family history of CAD, and smoking habit, compared to patients without CAD.
Onset of CAD
In the 101 patients with CAD, age by decade at the first onset of CAD is illustrated in Fig. 1 . The average age was 45.8 10.6 years in men and 59.0 9.5 years in women, and this is consistent with a previous report of Japanese FH patients 13) . Analysis of CAD onset in relation to the presence ( ) or absence ( ) of statin treatment showed that in the 66 FH men with CAD, 13 did and 53 did not have statin treatment, and in the 35 FH women with CAD, 12 did and 23 did not have statin treatment. The age distribution at the first onset of CAD in statin ( ) or statin ( ) patients is shown in Fig. 2 . The peak was at an older age in statin ( ) men and women (Panels A and B, respectively) compared to statin ( ). The lipid profile at the time of first onset of CAD in statin ( ) and statin ( ) patients is shown in Table 2 . Statin ( ) patients were older when CAD was identified and had lower TC and LDL-C levels than statin ( ) patients.
To identify the factors that may influence the age at which CAD developed in statin ( ) and statin ( ) patients, we analyzed covariates (ANCOVA; Table 3) , which included sex, smoking, BMI, hypertension, diabetes mellitus, family history of CAD, thickness of Achilles tendon, LDL-C levels, and the use of aspirin, probucol, and cholestyramine. We found that statin ( ) patients were older when CAD developed, about 10 years older for each variable compared to statin ( ) patients, which may be due to the use of statins and Values are shown as the mean SD except for triglyceride. For triglyceride, the median (range) is shown. BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; CAD, coronary artery disease the reduction of LDL-C.
To determine the impact of statin treatment on the age at which CAD developed, we analyzed the same data for the pre-and post-statin eras. Pravastatin was the first statin approved in Japan. Patients were divided into two groups: Group 1 developed CAD before the end of September 1989 (n 53) and Group 2 developed CAD from October 1989 (to June 2007; n 48). Of the 66 men with CAD, 39 were in Group 1 and 27 in Group 2, and of the 35 women with CAD, 14 were in Group 1 and 21 in Group 2. The men and women whose CAD developed after the beginning of October 1989 were older than those who developed CAD before that date (Fig. 3A, B) . At the 
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first clinic visit, no clinical differences were seen in these patients in average age, BMI, plasma lipid and lipoprotein profile, Achilles tendon thickness and the incidence of hypertension, diabetes mellitus, and family history of CAD (Table 4) ; however, significantly more of the patients who developed CAD before the end of September 1989 were smokers. Assessment of clinical parameters obtained at the time CAD was identified shows that patients who developed CAD after the beginning of October 1989 were older ( Table 5) ,
reflecting the influence of statins on the onset age of CAD (Fig. 3A, B) , and that TC and LDL-C levels were lower, reflecting that more of these patients were receiving lipid-lowering treatment than patients who developed CAD before this date.
Analysis of Factors that Affect Age at the First Onset of CAD
Age at the development of CAD in Groups 1 and 2 was analyzed using analysis of covariance (AN- Values are shown as the mean SD except for triglyceride. For triglyceride, the median (range) is shown. COVA; Table 6 ). Significant differences between groups were seen for sex, prevalence of smoking, LDL-C, and the use of statins, aspirin and probucol. After adjusting for these variables, statin use was independently associated with age at the onset of CAD.
Discussion
The mortality rate for CAD is 11 times higher in heterozygous FH patients than in the general population; thus, prevention of CAD is the key therapeutic goal for these patients 14) . Treatment to reduce high levels of LDL-C in FH patients was limited before statins became available, and a clinically meaningful decrease in LDL-C levels was difficult to obtain. Pravastatin was first introduced onto the Japanese market at the beginning of October 1989 and thereafter, LDL-C reductions of 20% to 30%, even in FH heterozygous patients, became possible 19) . Recently, the risk of myocardial infarction in heterozygous FH was reported to be reduced by 76%, similar to the general population of the Netherlands 20) . In the present paper, we assessed the impact of statin use on the clinical prognosis of Japanese FH patients visiting our lipid clinic by retrospectively analyzing their clinical records. The use of statins delayed the first CAD event by about 7 years in FH patients whose first event occurred after the introduction of statins, compared to FH patients whose first event occurred prior to the introduction of statins.
In this study, 101 of 329 (30.6%) consecutive heterozygotes of FH had clinical evidence of CAD. The profile of CAD patients is similar to previous reports, that is, more men than women 3, 21, 22) , and higher BMI, higher TC and LDL-C levels, lower HDL-C levels, and a higher incidence of hypertension, diabetes mellitus, family history of CAD, and smoking 3, 13, 23, 24) .
The time span of our study allowed us to assess the impact on the development of CAD of the introduction of statins onto the Japanese market at the beginning of October 1989. Comparing clinical parameters at the first clinic visit in the patients whose CAD developed before the end of September 1989 with after that date, revealed that only smoking was different, perhaps reflecting the social trend against smoking ( Table 4 ). In contrast, interesting differences between these groups were seen in relation to when they developed CAD. Patients who developed CAD prior to the introduction of statins were younger on average (46.9 years old) and had higher levels of TC and LDL-C (323 and 257 mg/dL, respectively). Two other prominent differences were the improved lipid-lowering drug regimens, including statins, cholestyramine, probucol, and aspirin, and a decline in the number of smokers. Notably, statin use was independently and significantly associated with age at CAD onset in the 101 FH patients on covariate analysis of factors known to affect the age of developing CAD. Besides these factors, many other factors should be considered for the potential influence on the onset age of CAD, such as the widespread recognition of FH and the regimen for the treatment of other risk factors, such as hypertension and diabetes mellitus. Nevertheless, we should conclude from this analysis that the use of statins is a major factor contributing to the improvement of the clinical prognosis of FH patients in Japan.
More recently, "strong" statins have become available, making it possible to reduce LDL-C levels to much lower levels compared to conventional statins in FH patients [25] [26] [27] . The possible impact of these stronger statins on delaying the development of CAD in FH patients will be of interest.
One diagnostic criterion for heterozygous FH in the existing guidelines is a family history of premature CAD [28] [29] [30] . However, our results suggest that this criterion may need to be reconsidered because of the proven ability of statin treatment to delay the development of CAD to an age similar to that in persons who do not have heterozygous FH.
We showed in this retrospective analysis that the development of CAD was delayed by about 7 years in FH patients whose CAD developed after the introduction of statins in Japan compared to those whose CAD developed before the current statin era.
